1. Food and Drug Administration. Xenotransplantation. Current as of 03/03/2021. https://www.fda.gov/vaccines-blood-biologics/xenotransplantation. Accessed 23 Aug 2022.
2. European Medicines Agency. Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on xenogeneic cell therapy. November 16, 2000. https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-cpmp-points-consider-xenogeneic-cell-therapy_en.pdf. Accessed 23 Aug 2022.
3. Think Tank, European Parliament. What if xenotransplantation was the answer to the donor organ shortage? At a Glance. 13-01-2022. https://www.europarl.europa.eu/thinktank/en/document/EPRS_ATA(2022)697212. Accessed 23 Aug 2022.
4. Food and Drug Administration: source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans guidance for industry. 2003, revised December 2016. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/source-animal-product-preclinical-and-clinical-issues-concerning-use-xenotransplantation-products. Accessed 23 Aug 2022.
5. Huang C-P, Yang C-Y, Shyr CR. Utilizing xenogeneic cells as a therapeutic agent for treating diseases. Cell Transplant. 2021;30:9636897211011995. https://doi.org/10.1177/09636897211011995.